Pharmacy Business for Sale: What Buyers Need to Know

How Pharmacy Businesses Are Valued

Independent pharmacies are valued on EBITDA multiples, typically in the **3.0x–5.5x** range, with the spread driven by script volume, payer mix quality, DIR fee exposure, and whether the pharmacy has revenue streams beyond standard dispensing.

Script count — the number of active prescriptions filled per month — is the primary revenue driver, but it is not the only valuation variable. A pharmacy filling 3,000 scripts per month at average gross profit of $12 per script generates $36K per month — but a pharmacy filling 2,400 scripts at $18 average gross profit generates $43K. Payer mix and reimbursement rates drive gross profit per script, not raw volume.

For compounding pharmacies — which have higher gross margins, less payer dependency, and a different regulatory profile — the valuation framework is meaningfully different. The compounding pharmacy acquisition guide covers how compound-specific revenue streams are valued.

For standard dispensing pharmacies, the pharmacy acquisition guide covers the full deal structure and what qualified buyers look for.

Script Volume and Payer Mix — The Two Key Metrics

Script volume tells you how many customers the pharmacy serves. Payer mix tells you how much each script is worth after network deductions and DIR fees.

**Active script count.** Request a trailing 12-month dispensing report from the pharmacy management system (PioneerRx, QS/1, Liberty). The report should show: total prescriptions dispensed by month, new versus refill ratio, and prescriptions by payer class. A pharmacy where 60%+ of volume is refills has a stable, recurring base. A pharmacy dependent on new prescriptions for volume has a less predictable future.

**Payer mix.** The three payer classes — Medicare Part D/PBM plans, Medicaid, and commercial insurance — pay dramatically different rates for the same prescription. Medicare Part D plans, processed through PBM networks (CVS Caremark, Express Scripts, OptumRx), have the most complex fee structure and the most significant DIR fee exposure. Medicaid typically pays lower rates than commercial insurance. A pharmacy with 70%+ commercial insurance has better reimbursement economics than one that is Medicare Part D-heavy.

**DIR fees.** Direct and Indirect Remuneration fees are PBM clawbacks applied retroactively to Medicare Part D prescriptions based on "performance metrics" that pharmacies often cannot control. DIR fees have been a major profitability erosion mechanism for independent pharmacies in recent years. Before valuing any pharmacy, request the last 24 months of DIR fee reconciliations from the PBM portals. Total DIR fees as a percentage of gross profit is the metric that matters.

Licenses, DEA Registration, and Regulatory Transfer

Pharmacy acquisitions are more regulated than most small business transactions. The regulatory transfer process is not a formality — it sets the deal timeline and, if handled incorrectly, can leave a buyer unable to legally dispense for weeks after close.

**State pharmacy license.** Every state requires a pharmacy to hold a state-issued pharmacy permit, and the permit must be in the name of the pharmacy entity. Most states require either a new license application under the new owner or a change-of-ownership notification that can take 30–60+ days to process. Contact your state board of pharmacy before signing the purchase agreement to confirm the transfer process and timeline.

**DEA registration.** The DEA registration (required to dispense controlled substances) is issued to a specific entity and pharmacist-in-charge (PIC). A change of ownership requires a new DEA registration application, which can take 4–6 weeks in some states. A pharmacy that cannot fill controlled substance prescriptions during this gap is operating at significantly reduced capacity. Coordinate DEA transfer as a parallel workstream to the state license application.

**Pharmacist-in-Charge.** Every pharmacy must have a licensed PIC whose license is registered with the state board for that location. If the selling owner is the PIC and is leaving at close, the buyer (or a hired pharmacist) must be registered as the new PIC before or immediately at close. This is a licensing dependency that must be planned for — not discovered on closing day.

SBA Financing for Pharmacy Acquisitions

Independent pharmacy acquisitions are strong SBA 7(a) candidates. Pharmacies have documented recurring script revenue, physical inventory that serves as partial collateral, and a business model that SBA lenders understand well — particularly in markets where pharmacies have been bought and sold multiple times through SBA programs.

For a $1.5M pharmacy acquisition: $150K equity injection (10%), $1.35M SBA 7(a) loan over 10 years at ~10.5%. Monthly debt service: approximately $18,200. Against a pharmacy generating $350K+ in adjusted EBITDA, the DSCR is 1.60x — well within SBA guidelines.

**Inventory is real collateral.** Pharmacies carry $80K–$250K in prescription drug inventory at cost. This tangible collateral improves the lender's security position meaningfully relative to pure service businesses. Confirm the inventory count and its value at the time of the offer — inventory fluctuates and needs to be reconciled at closing.

**PBM credentialing must transfer.** The buyer must apply for credentialing with each PBM network the pharmacy currently participates in. PBM credentialing applications take 30–60 days per network. If the buyer is not credentialed before close, the pharmacy cannot submit claims for that network post-close. Initiate PBM credentialing applications immediately at LOI execution.

Model your acquisition financing before engaging lenders. The SBA Loan Calculator shows your monthly payment and DSCR at any purchase price.

Due Diligence Priorities for Pharmacy Acquisitions

Pharmacy due diligence is more technical than most small business deals. These are the items that catch buyers off guard if not addressed before close.

**Pull PBM contracts and network agreements directly.** Request copies of all current PBM network participation agreements. Review termination provisions — some PBM contracts allow the PBM to terminate the agreement upon a change of ownership. A terminated PBM contract means the pharmacy cannot process claims for that network. Confirm with each major PBM that the existing contract will survive or be transferred.

**Audit prior authorization and audit exposure.** PBMs conduct pharmacy audits — retrospective reviews of claim submissions that can result in significant clawbacks if documentation is found deficient. Request the last three years of PBM audit results and any outstanding audit recoupments. Unresolved audits should be resolved or escrowed before close.

**Verify all controlled substance records with DEA compliance.** Request the last two years of DEA Form 222 and DEA 106 (theft/loss) records. Any pattern of controlled substance discrepancies is a compliance and liability issue that must be fully resolved before assuming ownership.

**Interview the pharmacist staff.** Confirm that the licensed pharmacists and technicians intend to remain post-close. A pharmacy that loses its only licensed staff pharmacist in the first 30 days is a pharmacy that cannot operate full hours.

For the full healthcare acquisition due diligence framework including HIPAA compliance and state healthcare board requirements, the healthcare business acquisition due diligence checklist covers the complete regulatory review process.

Structuring the Offer for a Pharmacy Acquisition

Pharmacy LOIs have specific provisions that generic templates miss.

**License transfer as a closing contingency.** The LOI should explicitly make closing contingent on state pharmacy license transfer, DEA registration transfer, and PBM credentialing of the new owner. Without this, a buyer can be legally obligated to close a transaction where they cannot legally operate the pharmacy.

**Inventory adjustment at closing.** Pharmacy inventory fluctuates daily. The purchase price should be stated net of inventory, with a separate inventory count conducted within 48–72 hours of closing and a price adjustment based on the count. The adjustment mechanism — who counts, what price list applies, how discrepancies are resolved — should be specified in the purchase agreement.

**Seller transition period.** Prescription customer relationships transfer smoothly when the selling pharmacist introduces the buyer to patients, staff, and prescribers in the weeks leading up to close. A 30–90 day seller transition agreement — with the seller working reduced hours as a consultant after close — is standard in pharmacy deals and worth negotiating for.

The LOI Generator produces a complete Letter of Intent for pharmacy acquisitions — including license transfer contingency, inventory adjustment mechanism, DEA transfer, PBM credentialing, and SBA financing terms — in under two minutes.